Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT06657690RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after immunotherapy
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Zhuhai, GuangzhouAges 18–70 - NCT07495397Recruiting
Daphnetin plus chemo for advanced ovarian cancer maintenance
This trial is testing a combination of two drugs—daphnetin capsules and a standard chemotherapy (TC regimen)—as a targeted maintenance therapy after initial surgery for advanced ovarian cancer. The goal is to see if this treatment can help keep the cancer from coming back.
Changchun, JilinAges 18–75 - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT07492394RecruitingPhase 2
Testing dalpiciclib with or without entinostat and letrozole for early breast cancer
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
Shijiazhuang, HebeiAges 18–75 - NCT07489716RecruitingPhase 2
Study of SHR-1826 for advanced non-small cell lung cancer
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07490301RecruitingPhase 2/Phase 3
Study of a new drug combo for first-line metastatic pancreatic cancer
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
New Haven, ConnecticutAges 18 years+ - NCT07493044RecruitingPhase 1
Study of Super CAR-T for advanced liver cancer (GPC3-positive)
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
Guangzhou, GaungdongAges 18–75 - NCT06472713RecruitingPhase 2
Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Zhuhai, GuangdongAges 18–70 - NCT06649708RecruitingPhase 1/Phase 2
Study of HX044 for advanced solid tumors
This trial tests an experimental drug called HX044 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and helps shrink tumors.
Blacktown, New South WalesAges 18–75 - NCT07483970RecruitingPhase 1
JL19001 alone or with BCG for high-risk non-muscle invasive bladder cancer
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
Chengdu, SichuanAges 18 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT06774222RecruitingPhase 2
Fruquintinib plus chemo for HER2-negative gastric cancer
This trial tests adding fruquintinib (a targeted drug that blocks blood vessel growth) to chemotherapy after surgery for HER2-negative stomach or gastroesophageal junction cancer. It is for patients whose tumor did not respond well to previous treatment before surgery.
ZhengzhouAges 18–75 - NCT07484724RecruitingPhase 2
JS212 combination therapy for advanced esophageal cancer
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07488572Enrolling by invitationPhase 2
AK112 for advanced clear cell kidney cancer
This study tests a new drug called AK112 (Yiwoxidan Anti) in people with advanced clear cell kidney cancer who cannot take TKI medications. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07486947Recruiting
Studying nutrition and metabolism in lung cancer
This trial looks at how lung cancer and treatment affect your nutrition and metabolism. It aims to create a personalized nutrition plan for people with lung cancer.
Parma, ParmaAges 18–85 - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06761651RecruitingPhase 1
TAVO412 for advanced solid tumors with EGFR, MET, or VEGF changes
This trial tests a new drug, TAVO412, for people with advanced solid tumors that have not responded to other treatments. It focuses on cancers with specific markers (EGFR, MET, or VEGF) and aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05991583RecruitingPhase 1/Phase 2
IBB0979 for advanced solid tumors that have stopped responding to treatment
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07480213RecruitingPhase 1/Phase 2
CAR-NK cell therapy for relapsed small cell lung cancer
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07478302RecruitingPhase 1
A study of two drugs for untreated advanced liver cancer
This trial tests a combination of two medications, SHR-2524 and bevacizumab, as a first treatment for people with advanced hepatocellular carcinoma (a type of liver cancer) that has not been treated with cancer drugs before. The goal is to see if this combination can help shrink or control the cancer.
Fuzhou, FujianAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Little Rock, ArkansasAges 18 years+ - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.